NASDAQ:ARCT Arcturus Therapeutics (ARCT) Stock Price, News & Analysis $24.07 +1.09 (+4.74%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$23.26▼$25.1750-Day Range$21.45▼$44.3952-Week Range$17.52▼$45.00Volume353,251 shsAverage Volume521,283 shsMarket Capitalization$648.21 millionP/E RatioN/ADividend YieldN/APrice Target$67.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrends Get Arcturus Therapeutics alerts: Email Address Arcturus Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside180.8% Upside$67.60 Price TargetShort InterestBearish21.15% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.33Based on 5 Articles This WeekInsider TradingSelling Shares$1.05 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.39) to ($0.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.32 out of 5 starsMedical Sector571st out of 936 stocksPharmaceutical Preparations Industry258th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingArcturus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageArcturus Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Arcturus Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted21.15% of the float of Arcturus Therapeutics has been sold short.Short Interest Ratio / Days to CoverArcturus Therapeutics has a short interest ratio ("days to cover") of 8.7.Change versus previous monthShort interest in Arcturus Therapeutics has recently increased by 11.32%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldArcturus Therapeutics does not currently pay a dividend.Dividend GrowthArcturus Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ARCT. Previous Next 2.4 News and Social Media Coverage News SentimentArcturus Therapeutics has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Arcturus Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 5 people have searched for ARCT on MarketBeat in the last 30 days. This is a decrease of -55% compared to the previous 30 days.MarketBeat Follows6 people have added Arcturus Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arcturus Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,045,390.00 in company stock.Percentage Held by Insiders13.80% of the stock of Arcturus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.54% of the stock of Arcturus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arcturus Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Arcturus Therapeutics are expected to grow in the coming year, from ($4.39) to ($0.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcturus Therapeutics is -6.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcturus Therapeutics is -6.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcturus Therapeutics has a P/B Ratio of 2.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Arcturus Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Arcturus Therapeutics Stock (NASDAQ:ARCT)Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.Read More ARCT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARCT Stock News HeadlinesJuly 23 at 4:27 PM | markets.businessinsider.comPiper Sandler Reaffirms Their Buy Rating on Edgewise Therapeutics (EWTX)July 18, 2024 | businesswire.comArcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 18, 2024 | businesswire.comArcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024July 18, 2024 | americanbankingnews.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Sees Large Increase in Short InterestJune 20, 2024 | businesswire.comArcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of DirectorsJune 8, 2024 | seekingalpha.comArcturus: A Hidden Gem In The Biotech SectorMay 28, 2024 | msn.comArcturus Therapeutics' Early Cystic Fibrosis Trial Results Encouraging - Analyst Cautiously OptimisticJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 28, 2024 | marketwatch.comArcturus Therapeutics Shares Jump 23% on Positive Observations for Potential Cystic Fibrosis TreatmentMay 28, 2024 | businesswire.comArcturus Therapeutics Announces Positive Development for Cystic Fibrosis ProgramMay 27, 2024 | msn.comCSL and Arcturus Announce Breakthrough COVID-19 Vaccine Study ResultsMay 20, 2024 | businesswire.comNature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 VaccineMay 20, 2024 | prnewswire.comNature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 VaccineMay 17, 2024 | markets.businessinsider.comBuy Rating Affirmed for Tenaya Therapeutics Amidst Promising Gene Therapy AdvancesMay 15, 2024 | businesswire.comArcturus Therapeutics to Attend Upcoming Investor & Scientific ConferencesMay 12, 2024 | msn.comArcturus Therapeutics (NASDAQ:ARCT) Making Significant Strides Towards GrowthMay 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Arcturus Therapeutics Amidst Strong Financial Outlook and Promising Clinical AdvancementsSee More Headlines Receive ARCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcturus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/26/2024Next Earnings (Confirmed)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ARCT CUSIPN/A CIK1410997 Webwww.arcturusrx.com Phone(858) 900-2660FaxN/AEmployees180Year FoundedN/APrice Target and Rating Average Stock Price Target$67.60 High Stock Price Target$90.00 Low Stock Price Target$48.00 Potential Upside/Downside+180.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($3.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,730,000.00 Net Margins-81.59% Pretax Margin-82.40% Return on Equity-37.61% Return on Assets-23.99% Debt Debt-to-Equity RatioN/A Current Ratio3.26 Quick Ratio3.26 Sales & Book Value Annual Sales$169.93 million Price / Sales3.81 Cash FlowN/A Price / Cash FlowN/A Book Value$10.42 per share Price / Book2.31Miscellaneous Outstanding Shares26,930,000Free Float23,215,000Market Cap$648.21 million OptionableOptionable Beta2.64 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Joseph E. Payne M.Sc. (Age 52)Founder, President, CEO & Director Comp: $1.13MDr. Padmanabh Chivukula Ph.D. (Age 45)Founder, Chief Scientific Officer, COO & Secretary Comp: $787.5kMr. Andrew H. Sassine MBA (Age 60)CFO & Director Comp: $826.88kMs. Neda SafarzadehVice President and Head of IR/PR & MarketingMr. Lance KurataChief Legal OfficerMs. Natash O. BowmanChief Human Resources OfficerMr. Kevin T. SkolChief Business OfficerDr. Juergen Froehlich FCPh (Age 68)M.D., MBA, Chief Medical Officer Dr. Igor Smolenov M.D.Ph.D., Chief Development OfficerJoseph RobertsControllerMore ExecutivesKey CompetitorsStoke TherapeuticsNASDAQ:STOKRevance TherapeuticsNASDAQ:RVNCMersana TherapeuticsNASDAQ:MRSNShattuck LabsNASDAQ:STTKNGM BiopharmaceuticalsNASDAQ:NGMView All CompetitorsInsiders & InstitutionsARK Investment Management LLCBought 275,315 shares on 7/26/2024Ownership: 7.297%Bank of New York Mellon CorpBought 3,578 shares on 7/26/2024Ownership: 0.443%Allspring Global Investments Holdings LLCSold 21,737 shares on 7/26/2024Ownership: 0.029%Hennion & Walsh Asset Management Inc.Bought 2,730 shares on 7/20/2024Ownership: 0.129%Sumitomo Mitsui Trust Holdings Inc.Bought 286,546 shares on 7/19/2024Ownership: 5.804%View All Insider TransactionsView All Institutional Transactions ARCT Stock Analysis - Frequently Asked Questions How have ARCT shares performed this year? Arcturus Therapeutics' stock was trading at $31.53 on January 1st, 2024. Since then, ARCT stock has decreased by 23.7% and is now trading at $24.07. View the best growth stocks for 2024 here. How were Arcturus Therapeutics' earnings last quarter? Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) announced its quarterly earnings results on Wednesday, May, 8th. The biotechnology company reported ($1.00) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.17) by $0.17. The biotechnology company had revenue of $38.01 million for the quarter, compared to the consensus estimate of $22.12 million. Arcturus Therapeutics had a negative trailing twelve-month return on equity of 37.61% and a negative net margin of 81.59%. What is Joe Payne's approval rating as Arcturus Therapeutics' CEO? 11 employees have rated Arcturus Therapeutics Chief Executive Officer Joe Payne on Glassdoor.com. Joe Payne has an approval rating of 90% among the company's employees. 70.0% of employees surveyed would recommend working at Arcturus Therapeutics to a friend. Who are Arcturus Therapeutics' major shareholders? Top institutional investors of Arcturus Therapeutics include ARK Investment Management LLC (7.30%), Sumitomo Mitsui Trust Holdings Inc. (5.80%), Bank of New York Mellon Corp (0.44%) and Harbor Capital Advisors Inc. (0.24%). Insiders that own company stock include Ultragenyx Pharmaceutical Inc, Pad Chivukula, Magda Marquet and Keith C Kummerfeld. View institutional ownership trends. How do I buy shares of Arcturus Therapeutics? Shares of ARCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Arcturus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), Pfizer (PFE), OPKO Health (OPK) and NVIDIA (NVDA). This page (NASDAQ:ARCT) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcturus Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcturus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.